Clinical Trial: Trial of Dasatinib in Advanced Sarcomas
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Phase II Trial of Dasatinib in Advanced Sarcomas
Brief Summary: This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Detailed Summary:
Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):
Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.
Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment.
A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment.
Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur.
Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.
Sponsor: Sarcoma Alliance for Research through Collaboration
Current Primary Outcome: Evaluation of all lesions for progression or response will be made at 2-month intervals for the first 6 months and then every 3 months thereafter [ Time Frame: every 2 months ]
Original Primary Outcome: Evaluation of all lesions for progression or response will be made at 2-month intervals for the first 6 months and then every 3 months thereafter.
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Sarcoma Alliance for Research through Collaboration
Dates:
Date Received: April 20, 2007
Date Started: May 2007
Date Completion: May 2017
Last Updated: March 20, 2017
Last Verified: March 2017
